Agenus Inc. - Common Stock (NQ:AGEN)

7.670 +0.130 (+1.72%)

Delayed Quote Updated: 4:00 PM EDT, Oct 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Agenus Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Why Infinity Pharmaceuticals Shares Tumbled Around 38%; Here Are 79 Biggest Movers From Yesterday ↗

November 15, 2022

Gainers Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT) shares surged 113.8% to settle at $20.10 on Monday. Indivior PLC agreed to acquire Opiant Pharmaceuticals for $20.00 per share in cash, plus...

Via Benzinga

Agenus (AGEN) Q3 2022 Earnings Call Transcript ↗

November 08, 2022

AGEN earnings call for the period ending September 30, 2022.

Via The Motley Fool

VBI Vaccines, Agenus Ink Partnership For Combination Brain Cancer Therapy ↗

October 12, 2022

Via Benzinga

Why Agenus Stock Rose 18.4% on Thursday ↗

October 06, 2022

The company's shares climbed with help from insider buying.

Via The Motley Fool

Miniso Group, Monday.com And Other Big Gainers From Monday ↗

November 15, 2022

U.S. stocks closed lower on Monday, with the Dow Jones dropping more than 200 points. Here is the list of some big stocks recording gains in the previous session.

Via Benzinga

Why Opiant Pharmaceuticals Shares Are Trading Higher By 115%? Here Are 53 Stocks Moving In Monday's Mid-Day Session ↗

November 14, 2022

Gainers Freight Technologies, Inc. (NASDAQ: FRGT) shares surged 137% to $0.4901 after analysts at Chardan Capital initiated coverage of the stock with a $2.25 price target.

Via Benzinga

Short Volatility Alert: Agenus Inc. ↗

August 31, 2022

On Tuesday, shares of Agenus Inc. (NASDAQ: AGEN) experienced volatile short activity. After the activity, the stock price went down 0.00% to $2.66. The overall sentiment for AGEN has been Neutral.

Via Benzinga

Recap: Agenus Q2 Earnings ↗

August 09, 2022

Agenus (NASDAQ:AGEN) reported its Q2 earnings results on Tuesday, August 9, 2022 at 07:30 AM. Here's what investors need to know about the announcement.

Via Benzinga

Agenus Data at SITC 2022 Highlight Durable Responses of Botensilimab / Balstilimab Combination in Nine Different Treatment-Resistant Cancers

November 14, 2022

From Agenus Inc.

Via GlobeNewswire

360 DigiTech, HUTCHMED And Some Other Big Stocks Moving Higher In Today's Pre-Market Session ↗

November 14, 2022

U.S. stock futures traded lower this morning. Here are some big stocks recording gains in today’s pre-market trading session.

Via Benzinga

Agenus Provides Corporate Update and Third Quarter 2022 Financial Report

November 08, 2022

From Agenus Inc.

Via GlobeNewswire

10 Best Medical Stocks Under $5 ↗

October 29, 2022

The medical industry is one of the most lucrative sectors globally, and it is one that sees the highest spending in terms of research and development, and breakthrough advances through keeping up the...

Via Talk Markets

Agenus to Provide Corporate Update and Third Quarter 2022 Financial Report

October 25, 2022

From Agenus Inc.

Via GlobeNewswire

GSK’s older adult RSV vaccine candidate, containing Agenus’ QS-21 STIMULON™, shows 94.1% reduction in severe RSV disease and overall vaccine efficacy of 82.6% in pivotal trial

October 13, 2022

From Agenus Inc.

Via GlobeNewswire

VBI Vaccines and Agenus Announce Collaboration to Evaluate VBI-1901 in Combination with Anti-PD-1 Balstilimab in a Phase 2 Study in Primary Glioblastoma Patients

October 12, 2022

From Agenus Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Monday's After-Market Session ↗

October 10, 2022

Gainers Reshape Lifesciences (NASDAQ:RSLS) shares increased by 12.7% to $0.34 during Monday's after-market session. The market value of their outstanding shares is at $1.2 million.

Via Benzinga

Why Cyclerion Therapeutics Shares Traded Lower By Around 38%; Here Are 70 Biggest Movers From Yesterday ↗

October 07, 2022

Gainers Green Giant Inc. (NASDAQ: GGE) jumped 161.1% to close at $1.88 after dipping 29% on Wednesday.

Via Benzinga

Tilray Brands, Canopy Growth, Cronos Group And Other Big Gainers From Thursday ↗

October 07, 2022

U.S. stocks closed lower with the Dow Jones dropping more than 300 points on Thursday. Here is the list of some big stocks recording gains in the previous session.

Via Benzinga

Why Revelation Biosciences Shares Are Trading Higher By 29%, Here Are 50 Stocks Moving In Thursday's Mid-Day Session ↗

October 06, 2022

Gainers Statera Biopharma, Inc. (NASDAQ: STAB) rose 98% to $0.2777. Statera Biopharma was recently granted European patent number EP3206708 titled "Methods And Compositions For The Treatment Of...

Via Benzinga

Agenus to Host “The Road Taken” R&D Event on November 12, 2022

October 05, 2022

From Agenus Inc.

Via GlobeNewswire

Agenus to Present Botensilimab Data at a Plenary Session of the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

October 05, 2022

From Agenus Inc.

Via GlobeNewswire

7 Penny Stocks That Actually Have a Buy Rating ↗

September 19, 2022

Penny stocks are always a risky proposition. However, investors can still find penny stocks with buy ratings right now.

Via InvestorPlace

Important Biotech Catalysts For September 12, 2022 - End Of The Day Summary ↗

September 12, 2022

Via Benzinga

Agenus Begins Mid-Stage Global Studies On Colorectal And Skin Cancer Candidate ↗

September 12, 2022

Agenus (NASDAQ: AGEN) has initiated Phase 2 ACTIVATE trials of botensilimab to advance globally in metastatic patients who have progressed on available therapies. This global Phase 2 program include...

Via Benzinga

Agenus Earnings Perspective: Return On Capital Employed ↗

September 01, 2022

According to Benzinga Pro data, during Q2, Agenus (NASDAQ:AGEN) posted sales of $20.93 million. Earnings were up 2.71%, but Agenus still reported an overall loss of $49.23 million.

Via Benzinga

Recap Of Monday's Biotech Catalysts - End Of the Day Summary ↗

August 01, 2022

Via Benzinga

Agenus Commences Initial-Stage Advanced Tumors Study ↗

August 01, 2022

Agenus (NASDAQ: AGEN) has dosed the first patient in the Phase 1 clinical study of AGEN1571 in advanced solid tumors. AGEN1571is a novel anti-ILT2 antibody designed to modulate tumor-associated...

Via Benzinga

Agenus to Provide Corporate Update and Second Quarter 2022 Financial Report

July 27, 2022

Conference Call on Tuesday, August 9, 2022 at 8:30 a.m. ET

From Agenus Inc.

Via GlobeNewswire

Alphabet, Dyne Therapeutics And 74 Biggest Movers From Yesterday ↗

July 06, 2022

Gainers Enjoy Technology, Inc. (NASDAQ: ENJY) shares jumped 81.5% to close at $0.31 on Tuesday.

Via Benzinga

This Healthcare Stock Surges Around 115%, Here's 74 Biggest Movers From Yesterday ↗

June 30, 2022

Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) shares surged 114.3% to close at $0.2550 on Wednesday after the company announced it has terminated its previously announced at-the-market offering.

Via Benzinga

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.